Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mattheos Bobos

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Cancer Investigation|September 18, 2008
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluationGeorge Fountzilas, Mattheos Bobos, Anna Kalogera-Fountzila, et al.
Plos One|June 27, 2014
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsMaria Vassilakopoulou, Taiwo Togun, Urania Dafni, et al.
Anticancer Research|April 1, 2009
Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neckGeorge Fountzilas, Aristotelis Bamias, Anna Kalogera-Fountzila, et al.
Journal of Translational Medicine|October 25, 2012
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumabGeorge Fountzilas, Christos Christodoulou, Mattheos Bobos, et al.
Plos One|August 13, 2013
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialGeorge Fountzilas, Vassiliki Kotoula, Dimitrios Pectasides, et al.
Breast Cancer Research and Treatment|March 11, 2011
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) studyGeorge Pentheroudakis, Anna Batistatou, Konstantine T Kalogeras, et al.
Pathology Oncology Research : POR|August 8, 2014
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumabKitty Pavlakis, Mattheos Bobos, Anna Batistatou, et al.
Journal of Neuro-Oncology|July 9, 2017
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)Christos Christodoulou, Anna Kalogera-Fountzila, Vasilios Karavasilis, et al.
Plos One|December 7, 2018
Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancerGenovefa Polychronidou, Vassiliki Kotoula, Kyriaki Manousou, et al.
BMC Clinical Pathology|July 3, 2014
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studiesTriantafyllia Koletsa, Flora Stavridi, Mattheos Bobos, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Cancer Investigation|September 18, 2008
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluationGeorge Fountzilas, Mattheos Bobos, Anna Kalogera-Fountzila, et al.
Plos One|June 27, 2014
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsMaria Vassilakopoulou, Taiwo Togun, Urania Dafni, et al.
Anticancer Research|April 1, 2009
Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neckGeorge Fountzilas, Aristotelis Bamias, Anna Kalogera-Fountzila, et al.
Journal of Translational Medicine|October 25, 2012
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumabGeorge Fountzilas, Christos Christodoulou, Mattheos Bobos, et al.
Plos One|August 13, 2013
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialGeorge Fountzilas, Vassiliki Kotoula, Dimitrios Pectasides, et al.
Breast Cancer Research and Treatment|March 11, 2011
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) studyGeorge Pentheroudakis, Anna Batistatou, Konstantine T Kalogeras, et al.
Pathology Oncology Research : POR|August 8, 2014
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumabKitty Pavlakis, Mattheos Bobos, Anna Batistatou, et al.
Journal of Neuro-Oncology|July 9, 2017
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)Christos Christodoulou, Anna Kalogera-Fountzila, Vasilios Karavasilis, et al.
Plos One|December 7, 2018
Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancerGenovefa Polychronidou, Vassiliki Kotoula, Kyriaki Manousou, et al.
BMC Clinical Pathology|July 3, 2014
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studiesTriantafyllia Koletsa, Flora Stavridi, Mattheos Bobos, et al.
Pageof 10